Cargando…
Noncoding RNA Profile in Reovirus Treated KRAS-Mutated Colorectal Cancer Patients
Purpose: To investigate the alterations in the expression of noncoding, micro, and small RNA expression during treatment with oncolytic reovirus in KRAS-mutated colorectal cancer. Methods: Oncolytic reovirus treatment was administered in phase 1 clinical trial (NCT01274624) for 5 days every 28 days,...
Autores principales: | Saperstein, Rafael, Goel, Sanjay, Maitra, Radhashree |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594459/ https://www.ncbi.nlm.nih.gov/pubmed/37873786 http://dx.doi.org/10.3390/diseases11040142 |
Ejemplares similares
-
Transcriptome Signature of Immune Cells Post Reovirus Treatment in KRAS Mutated Colorectal Cancer
por: Fogel, Elisha J, et al.
Publicado: (2021) -
Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan
por: Maitra, Radhashree, et al.
Publicado: (2014) -
Therapeutic Targets of KRAS in Colorectal Cancer
por: Rahman, Shafia, et al.
Publicado: (2021) -
Toll-like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer
por: Maitra, Radhashree, et al.
Publicado: (2017) -
Immune characterization of metastatic colorectal cancer patients post reovirus administration
por: Parakrama, Ruwan, et al.
Publicado: (2020)